CoChat

Sarcomere Gene Mutation correction

Kaul, Sanjiv, Heitner, Stephen B, Mitalipov, Shoukhrat · 2018 · European Heart Journal

The DOI matches its Crossref record.

Abstract

Correction of a Sarcomere Gene Mutation Responsible for Hypertrophic Cardiomyopathy in Human Embryos and its implications for inherited gene defects in IVF Familial hypertrophic cardiomyopathy (HCM) is an inherited genetic disorder occurring in approximately 1 out of every 500 live births. Mutations in the MYBPC3 and MYH7 genes account for approximately 50% of all HCM. The MYBPC3 gene encodes for myosin binding protein C and founder mutations in this gene varies across regions, being as high as 5% in South and South-East Asia. In addition to HCM, mutations in MYBPC3 can also cause dilated cardiomyopathy in children and young adults. Both HCM and dilated cardiomyopathy can result in sudden cardiac death, particularly in young people, in addition to causing heart failure symptoms. Currently, medical management (β-blockers, calcium channel blockers, and disopyramide), surgical myectomy, implantable cardiac defibrillator, and heart transplantation are the major treatment options for patients with HCM. Most HCM patients surviving to adulthood are heterozygous carriers of one mutant copy of MYBPC3 or MYH7, with very few having double or compound mutations. These patients frequently parent children and if a spouse does not have the mutation, the children will have a 50% chance of inheriting the mutation. Parents can opt for pre-implantation genetic diagnosis (PGD) after invitro fertilization (IVF) so that only embryos free of mutation can be implanted. In this instance, at least half of the embryos—those carrying the mutation—would need to be discarded or abandoned, significantly reducing the efficacy of IVF. A more desirable approach would be to correct the mutation at the time of IVF so that most, if not all, embryos are free of the genetic defect and are used for reproduction. We have recently shown that such pre-emptive correction can be achieved by activating the embryo’s own gene repair mechanisms in response to the DNA break at the mutation site induced by Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas 9. We used sperm from a HCM patient carrying the heterozygous MYBPC3 deletion to fertilize eggs from healthy women. Figure 1 shows images of human egg just before (Figure 1A) and after (Figure 1B) introducing a micropipette through which sperm and CRISPR/Cas 9 would be introduced. CRISPR/Cas 9 was designed to identify and induce a double strand DNA break at the mutant MYBPC3 gene but not in the normal wild type allele. CRISPR/Cas 9 along with a short DNA repair template was introduced into eggs during fertilization with the mutant MYBPC3 sperm and heterozygous embryos were allowed to develop to the 8-cell stage and then were used for on- and off-target analyses. Images of human egg before (A) and after (B) introduction of a micropipette through which sperm and Clustered Regularly Interspaced Short Palindromic Repeats/Cas 9 would be injected. Surprisingly, most embryos corrected the mutant gene deletion induced by CRISPR/Cas 9 using the normal female MYBPC3 allele as a template rather than using the DNA template supplied by us. This process was not seen in the patient’s induced pluripotent stem cells created from skin fibroblasts where an artificial DNA template introduced into the cell was used exclusively as a repair template. Although such inter-homolog DNA repair has been previously noted in plants and other model organisms, their frequency is believed to be low. Our observation was the first in humans and the correction occurred in approximately 75% of the embryos. We believe that with further understanding of the underlying repair mechanisms of the embryo as well as refinements in our techniques we could significantly increase the success rate, thus reducing or completely eliminating the need to discard patient embryos during IVF. The second important finding of our study was that we were able to reduce or eliminate mosaicism. This is a phenomenon where the sister cells from the same CRISPR/Cas 9 treated embryo contains different targeting and/or repair outcomes. Mosaicism would be unacceptable for clinical application, because it would escape detection by PGD during IVF. Pre-implantation genetic diagnosis is based on biopsy and testing of a single or few cells from a multicellular embryo, and thus it is only informative for detection of uniform (non-mosaic) genetic defects. In our first set of experiments, when CRISPR/Cas 9 was injected into human embryos 22 hours after fertilization, approximately a quarter of the resulting embryos were mosaic. In contrast, when CRISPR/Cas 9 was co-injected simultaneously with the sperm during fertilization, only 1 out of 58 (1.7%) embryos exhibited mosaicism. We believe the different results are related to the timing of the DNA synthesis within human embryos at the time of CRISPR/Cas 9 introduction. If the sperm DNA has already been replicated before attempted gene correction in the embryo two or more copies of the mutant gene would need to be

Overview

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehy179

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 2

Metadata

Authors
Kaul, S., Heitner, S. B., & Mitalipov, S.
Affiliations
Oregon Health & Science University (US)
Corresponding author
Kaul, Sanjiv
Venue
European Heart Journal
Published
2018-05-01
Volume
39
Issue
17
Pages
1506-1507
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2802547012
Cited by
2
References
0
Citations by year
2020: 1 · 2018: 1
FWCI
0.38
Type
journal article
Language
en
Open access
closed
Locations
  • European Heart Journal (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords
MYBPC3, MYH7, preimplantation genetic diagnosis, CRISPR/Cas9, human embryo, founder mutation, dilated cardiomyopathy, sudden cardiac death, heterozygous carriers, DNA double-strand break repair, inherited genetic disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sarcomere Gene Mutation correction. https://app.cochat.ai/papers/10.1093/eurheartj/ehy179
The paper
Kaul, S., Heitner, S. B., & Mitalipov, S. (2018). Sarcomere Gene Mutation correction. European Heart Journal. https://doi.org/10.1093/eurheartj/ehy179

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.